Status:
COMPLETED
Study of the Effect of Telemedicine on Glycemic Control for Patients With Diabetes and Treated With Insulin
Lead Sponsor:
Centre Hospitalier Sud Francilien
Conditions:
Diabetes
Eligibility:
All Genders
12+ years
Brief Summary
The purpose of this study is to assess glycemic control changes in insulin-treated patients with diabetes using a continuous glucose monitoring CGM system through the ETAPES telemedicine program.
Detailed Description
Diabetes is currently one of the major health challenges. According to the International Diabetes Federation (IDF), the number of people with diabetes has tripled in the last 20 years and will reach 4...
Eligibility Criteria
Inclusion
- For people with T1D, inclusion criteria in the ETAPES program were:
- new onset diabetes (\< 6 months) or diabetes duration \> 6 months with HbA1C ≥ 8% twice over the last 6 months in people aged over 18 years
- new onset diabetes (\< 6 months) or diabetes duration \> 6 months with HbA1C ≥ 8.5% twice over the last 6 months in people aged between 12 and 17 years.
- For people with T2D, inclusion criteria were diabetes duration \> 12 months with HbA1C ≥ 9% twice over the last 6 months in people aged over 18 years.
Exclusion
- patients objecting to research
Key Trial Info
Start Date :
May 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 8 2021
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT04883372
Start Date
May 22 2021
End Date
June 8 2021
Last Update
June 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France, 91106